Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Exploring Trends in Life Sciences Consulting: What's Shaping the Industry?

Jan 20, 2026

The Evolving Landscape of Life Sciences Consulting

The life sciences consulting industry is undergoing significant transformation, driven by technological advancements, regulatory changes, and evolving client needs. As companies strive to innovate and adapt, consulting firms play a crucial role in guiding them through complex challenges. In this blog post, we'll explore the key trends shaping this dynamic sector.

life sciences consulting

Technological Integration

One of the most impactful trends in life sciences consulting is the integration of advanced technologies. With the rise of artificial intelligence, big data, and machine learning, consultants are equipped with tools to provide deeper insights and more accurate forecasts. These technologies enable life sciences firms to optimize research and development processes, improve patient outcomes, and enhance operational efficiency.

Consulting firms are also helping clients leverage digital health solutions, such as telemedicine and wearable devices, to improve patient engagement and data collection. This technological shift is not just about adopting new tools but also about transforming the way companies approach problem-solving and innovation.

Regulatory Changes

The life sciences industry is heavily regulated, and staying compliant with ever-changing laws can be daunting. Consulting firms are essential in helping companies navigate this complex landscape. Recent trends include a focus on personalized medicine and biosimilars, each with its own set of regulatory challenges.

regulatory compliance

Consultants are increasingly involved in shaping regulatory strategies, ensuring that their clients can bring new products to market quickly and cost-effectively. This proactive approach helps companies avoid potential pitfalls and maintain a competitive edge.

Focus on Sustainability

Sustainability has become a critical consideration for life sciences companies. From reducing carbon footprints to ensuring ethical sourcing of materials, consulting firms are guiding clients in implementing sustainable practices. This trend is driven by both consumer demand and regulatory pressure to adhere to environmental standards.

Consultants are helping companies not only comply with regulations but also leverage sustainability as a strategic advantage, enhancing brand reputation and driving long-term growth.

sustainability life sciences

Patient-Centric Models

The shift towards patient-centric models is another significant trend in the life sciences consulting industry. Companies are increasingly focusing on improving patient experiences and outcomes, and consultants play a crucial role in this transformation. By adopting a more holistic approach, firms can better understand patient needs and tailor their services accordingly.

Consulting firms are advising on strategies to enhance patient engagement, from personalized treatment plans to improved communication channels. This patient-first mindset is reshaping the industry and setting new standards for success.

Globalization and Market Expansion

As life sciences companies look to expand globally, they face diverse challenges in different markets. Consulting firms offer valuable insights into regional dynamics, helping clients navigate cultural, economic, and regulatory complexities. This expertise is crucial for successful market entry and expansion strategies.

global market expansion

By understanding local nuances and leveraging global networks, consultants enable companies to seize new opportunities and drive international growth.

Conclusion

The life sciences consulting industry is at the forefront of innovation and change, guiding companies through a landscape marked by technological advances, regulatory shifts, and evolving consumer expectations. By embracing these trends, consulting firms help their clients not only survive but thrive in a rapidly changing world. As we look to the future, the role of consultants will continue to be pivotal in shaping the life sciences sector.